Mannkind CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
MNKD
Mannkind CORPMannKind Corporation reported a 22% increase in total revenue for 2025, driven by product sales and collaborations, alongside strategic acquisitions and pipeline advancements.
NASDAQ
MNKD
Mannkind CORP10-K: MannKind Corporation Reports Positive Net Income for 2024, Driven by Tyvaso DPI and Afrezza Sales
MannKind Corporation's 2024 10-K filing reveals a return to profitability, driven by increased sales of Tyvaso DPI and Afrezza, alongside strategic pipeline advancements.
NASDAQ
MNKD
Mannkind CORPMannKind Corporation's 10-K filing details its capital structure, business operations, and strategic focus on developing and commercializing innovative therapeutic products and devices.